Mitogenic signal transduction pathways in meningiomas: Novel targets for meningioma chemotherapy?

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 12, 2005, Pages 1029-1036

  Johnson, Mahlon ^a,c   Toms, Steven ^b  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Growth factor receptors; Meningiomas; Signal transduction pathways

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CARBOPLATIN; CETUXIMAB; CISPLATIN; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C GAMMA1; PROSTAGLANDIN SYNTHASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RII 5777; SCH 66366; SMAD PROTEIN; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GLIOMA; GROWTH REGULATION; HUMAN; MENINGIOMA; MITOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; CELL DIVISION; METABOLISM; MITOSIS; ONCOLOGY; PATHOLOGY; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; HUMANS; MEDICAL ONCOLOGY; MENINGEAL NEOPLASMS; MENINGIOMA; MITOSIS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33644804422     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000189834.63951.81     Document Type: Review

References (80)

1. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: A review. J Neurooncol 1996;29:197-205
2. Maier H, Ofner D, Hittmair A, et al. Classic, atypical and anaplastic meningioma: Three histopathological subtypes of clinical relevance. J Neurosurg 1992;77:616-23
3. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 637 patients. A multivariate analysis. Surg Neurol 1986;26:461-69
4. Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: Outcomes and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 1998;73:936-42
5. Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: An analysis of histologic parameters. Am J Surg Pathol 1997;21:1455-65
6. McMullen KP, Stieber VW. Meningioma: Current treatment options and future directions. Curr Treat Options Oncol 2004;5:499-50
7. Morita A, Coffey RJ, Foote RL, et al. Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: Experience in 88 patients. J Neurosurg 1999;90:42-49
8. Lamberts SW, Tanghe HL, Avezaat CJ, et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psych 1992;55:486-90
9. Kaba SE, DeMonte F, Buner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997;40:271-75
10. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II Decrease in size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1977;86:840-44
11. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neuro-Oncol 2004;70:183-202
12. Gusella JF, Ramesh V, MacCollin M, et al. Merlin: The neurofibromatosis 2 tumor suppressor. Biochem Biophys Acta 1999;1423:M29-36
13. Antinheimo J, Haapasalo H, Haltia M, et al. Proliferation potential and histologial features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 1997;87:610-14
14. Lamszus K, Vahldeik F, Mautner VF, et al. Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 2000;59:504-12
15. Dumanski JP, Rouleau GA, Nordenskjold M, et al. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 1990;50:5863-67
16. Wellenreuther R, Kraus JA, Lenartz D, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995;146:827-33
17. Vogel Y, Lenartz D, Schramm J, et al. Quantitative analysis of neurfibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab Invest 1997;77:601-6
18. Rutledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-84
19. Lee JH, Sundaram V, Stein DJ et al. Reduced expression of Schwannomin/merlin in human sporadic meningiomas. Neurosurgery 1997;40:578-87
20. Weisman AS, Raguet SS, Kelly PA. Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 1987;47:2172-76
21. Jones NR, Rossi ML, Gregoriou M, et al. Epidermal growth factor receptor expression in 72 meningiomas. Cancer 1990;66:152-55
22. Johnson MD, Horiba M, Arteaga C. The epidermal growth factor receptor is associated with phospholipase C γ in meningiomas. Human Pathol 1994;25:146-53
23. Carroll RS, Black PM, Zhang J, et al. Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 1997;87:315-23
24. Lingood RM, Hsu DW, Efird JT, et al. TGF-alpha expression in meningioma-tumor progression and therapeutic response. J Neuro-Oncol 1995;26:45-51
25. Hsu QW, Efird JT, Hedley-Whyte ET. MIB-1(Ki-67) index and transforming growth factor alpha (TGF-alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 1998;24:441-52
26. Van Setten GB, Edstrom L, Stibler H, et al. Levels of transforming growth factor alpha (TGF-α) in human cerebrospinal fluid. Int J Dev Neurosci 1999;17:131-34
27. Wang J-L, Nister M, Hermansson M, Westermark B, et al. Expression of PDGF β-receptors in human meningioma cells. Int. J. Cancer 1990;46:772-78
28. Maxwell M, Galanopoulos T, Hedley-Whyte ET et al. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 1990;46:16-21
29. Shamah SM, ALberta JA, Giannobile WV, et al. Detection of activated platlet-derived growth factor receptors in human meningioma. Cancer Res 1997;57:4141-47
30. Adams EF, Schrell UMH, Thieruf P, et al. Autocrine control of human meningioma proliferation: Secretion of platelet-derived growth factor-like molecules. Int J Cancer 1991;49:398-402
31. Todo T, Adams EF, Fahlbusch R, et al. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurgery 1996;84:852-59
32. Nister M, Enbland P, Backstrom G, et al. Platelet-derived growth factor (PDGF) in neoplastic and non-neoplastic cystic lesions of the central nervous system and in the cerebrospinal fluid. Br J Cancer 1994;69:952-56
33. Nordqvist AC, Peyrard M, Petterson H, et al. A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas. Cancer Res 1997;57:2611-14
34. Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 2002;161:665-72
35. Nordqvist AC, Mathiesen T. Expression of IGF-II, IGFBP-2, -5 and -6 in meningioma with different brain invasiveness. J Neuro-Oncol 2002;57:19-26
36. Pronk GL, Bos JL. The role of p21 ras in receptor tyrosine kinase signaling. Biochim Biophys Acta 1994;1198:131-47
37. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411: 355-65
38. Shu J, Lee JH, Harwalkar JA, et al. Adenovirus-mediated gene transfer of dominant negative H-ras inhibits proliferation of primary meningioma cells. Neurosurgery 1999;44:579-87
39. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP Kinase cascades. Adv Cancer Res 1998;74:49-139
40. Marshall MS. Ras target proteins in eukaryotic cells. FASEB J 1995;9:1311-18
41. Kock W. Meaningful relationships: The regulation of the Ras/Raf/Mek/ERK pathway by protein interactions. Biochem J 2000;351:289-305
42. Sivaraman VS, Wang H, Nuvovo GJ, et al. Hyperexpression of mitogen-activated kinase in human breast carcinoma. J Clin Invst 1997;7:1478-83
43. Mandell JW, Hussaini IM, Zecevic M, et al. In situ visualization of intratumor growth factor signaling. Am J Pathol 1998;153:1411-23
44. Johnson MD, Woodard A, Kim P, et al. Evidence for mitogen associated protein kinase activation and transduction of mitogenic signals from platelet derived growth factor in human meningioma cells. J Neurosurg 2001;94:303-10
45. Mawrin C, Sasse T, Kirches E, et al. Different activation of mitogen activated protein kinase and Akt signalling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 2005;11:4074-82
46. Nicholson KM, Anderson NG. The Akt/PKB signaling pathway in human malignancy. Cell Signal 2002;14:381-95
47. Walker TR, Moore SM, Lawson MF, et al. Platelet-derived growth factor-BB and thrombin activate phophoinositide 3-kinase and protein kinase B: Role in mediating airway smooth muscle proliferation. Mol Pharmacol 1998;54:1007-15
48. Roche S, Koegl M, Courtneidge SA. The phosphatidylinositol 3-kinase A is required for DNA synthesis by some but not all growth factors. PNAS 1994;91:9185-89
49. Shayesteh L, Lu Y, Kuo W-L et al. PI3KCA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102
50. Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH33T3 cells. Am J Pathol 2001;159:431-37
51. S6K pathway activation and transduction of mitogenic signals by platelet derived growth factor in human meningioma cells. J Neurosurg 2002;97:668-75
52. Conway A-M, Rakhit S, Pyne S, et al. Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: Role pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochem J 1999;337:171-77
53. Yart A, Laffargue M, Mayeux P, et al. A critical role for phosphoinositide 3-kinase upstream of Gab 1 and SHP2 in the activation of Ras and mitogen-activated protein kinase by epidermal growth factor. J Biol Chem 2001;276:8856-64
54. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71
55. Gire V, Marshall C, Wynford-Thomas D. PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 2000;19:2269-76
56. Walker TR, Moore SM, Lawson MF, et al. Platelet-derived growth factor-BB and thrombin activate phophoinositide 3-kinase and protein kinase B: Role in mediating airway smooth muscle proliferation. Mol Pharmacol 1998;54:1007-15
57. Lin L-L, Wartmann M, Lin AY, et al. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993;27:269-78
58. Castelli MG, Chiabrando C, Fanelli R, et al. Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 1989;15:1505-8
59. Gaetani P, Butti G, Chiabrando C, et al. A study of the biological behavior of human brain tumors. Part I. Arachidonic acid metabolism and DNA content. J Neuro-Oncol 1991;10:233-40
60. Wang D, Buchanan FG, Wang H, et al. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005;65:1822-29
61. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 2003;4:431-36
62. Pai R, Soreghan B, Szabo II et al. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93
63. Wang Z, Gluck S, Zhang L, et al. Requirement for phospholipase C-1 enzymatic activity in growth factor-induced mitogenesis. Mol Cell Biol 1998;18:590-97
64. Wahl MI, Olashaw NE, Nishibe S, et al. Platelet-derived growth factor induces rapid and sustained tyrosine phosphorylation of phospholipase C-γ in quiescent BALB/c 3T3 cells. Mol Cell Biol 1989;9:2934-43
65. Buckley CT, Sekiya F, Kim YJ, et al. Identification of phospholipase C-1 as a mitogen-activated protein kinase substrate. J Biol Chem 2004;40:41807-14
66. Johnson MD, Federspiel CF, Gold LI, et al. Transforming growth factor-β and transforming growth factor-β receptor expression in human meningioma cells. Am J Path 1992;141:631-42
67. Johnson MD, Okediji E, Woodard A. Transforming growth factor-β Effects on meningioma cell proliferation and signal transduction pathways. J Neuro-Oncol 2004;66:9-16
68. Johnson MD, Gold LI, Moses HL. Evidence for TGF-β expression in human leptomeningeal cells and TGF-β-like activity in human cerebrospinal fluid. Lab Invest 1992;67:360-68
69. Jennings MT, Maciunas RJ, Carver R, et al. TGF-β 1 and TGF-β 2 are potential growth regulators for low grade and malignant gliomas in vitro: Evidence in support of an autocrine hypothesis. Int J Cancer 1991;49:129-39
70. Fan DS, Chakrabarty C, Seid CW, et al. Clonal stimulation or inhibition of human colon carcinomas and human renal carcinomas mediated by transforming growth factor-beta 1. Cancer Commun 1989;1:117-25
71. Manning AM, Williams AC, Game SM, et al. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-Beta): Conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 1991;6:1471-76
72. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000;12:235-43
73. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004;11:689-708
74. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. European J Cancer 2002;38:1685-1700
75. Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy naïve patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002;13(Suppl 5): 2-3
76. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41
77. Johnson MD, Woodard A, Okediji EJ, et al. Lovastatin is a potent inhibitor of meningioma cell proliferation: Evidence for inhibition of a mitogen associated protein kinase. J Neuro-Oncol 2002;56:133-42
78. Singer CF, Hudelist G, Lamm W, et al. Expression of tyrosine kinases I human malignancies as potential targets for kinase specific inhibitors. Endocrine-related Cancer 2004;11:861-69
79. Huang S, Armstrong EA, Benavente S, et al. Dual-agent targeting of the epidermal growth factor (EGFR): combining anti-EGFR antibody and tyrosine kinase inhibitor. Cancer Res. 2004;64:5355-62
80. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-28